SCHEMBL3608916

SCHEMBL3608916

C=Cc1c(C)nn(C)c1Oc1cc(O[C@@H](C)C(=O)O)c(Cl)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GPBAR1 Q8TDU6 7/20 0.35
MAPT P10636 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
PPARG P37231 2/20 0.33
GAA P10253 1/20 0.32
NR2F2 P24468 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603940 1.00 KDM4E (0.39) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3605072 1.00 KDM4E (0.39) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3610418 0.91 SMN1; SMN2 (0.37) KDM4EALDH1A1SMN1; SMN2CYP1A2CYP2C9
SCHEMBL3611050 0.90 SMN1; SMN2 (0.48) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3597585 0.90 SMN1; SMN2 (0.48) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3617128 0.90 SMN1; SMN2 (0.38) KDM4ESMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL3603459 0.90 CYP2C9 (0.38) KDM4EALDH1A1HPGDSMN1; SMN2CYP1A2
SCHEMBL3606304 0.90 PPOX (0.40) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3607646 0.88 KDM4E (0.38) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL3609672 0.88 ALDH1A1 (0.37) KDM4EALDH1A1HSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US claimed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP claimed
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R KDM4E 2049/4885ALDH1A1 365/4885HSD17B10 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.